13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India

PHASE4CompletedINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC
Interventions
BIOLOGICAL

13-valent Pneumococcal conjugate vaccine

1 dose (0.5 mL/ pre-filed syringe) of 13vPnC administered at visit 1

PROCEDURE

Blood sample collection

10 mL of blood will be collected just before and approximately 1 month after vaccination.

Trial Locations (16)

221005

Samvedna Hospital, Varanasi

380016

B. J. Medical College & Civil Hospital, Ahmedabad

391760

S.B.K.S Medical Institute & Research Centre, Vadodara

400007

Bhatia Hospital, Mumbai

411007

Medipoint Hospitals Pvt. Ltd., Pune

411018

Padmashree Dr. D. Y. Patil Medical College, Pune

411019

Niramaya Hospital, Chinchwad Pune

422002

Supe Heart & Diabetes Hospital and Research Centre, Nashik

422005

Chopda Medicare and Research Centre Pvt. Ltd, Nashik

440015

Orange City Hospital and Research Institute, Nagpur

530002

King George Hospital, Visakhapatnam

560054

M.S. Ramaiah Cliical Research Centre, M.S. Ramaiah Medical College & Hospitals, Bangalore

M.S. Ramaiah Medical College and Hospitals, Bangalore

570001

Cheluvamba Hospital, Mysore

580021

Sushruta Multispeciality Hospital & Research Centre Pvt. Ltd., Hubli

632 004

Christian Medical College, Vellore

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02034877 - 13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India | Biotech Hunter | Biotech Hunter